Compare MBWM & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBWM | CRVS |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 1997 | 2016 |
| Metric | MBWM | CRVS |
|---|---|---|
| Price | $60.30 | $11.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $55.67 | $30.17 |
| AVG Volume (30 Days) | 79.5K | ★ 861.2K |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | 10.95 | ★ 48.04 |
| EPS | ★ 2.82 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.28 | N/A |
| Revenue Next Year | $4.67 | N/A |
| P/E Ratio | $21.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.75 | $6.39 |
| 52 Week High | $62.95 | $26.95 |
| Indicator | MBWM | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 50.33 | 34.36 |
| Support Level | $58.49 | $11.13 |
| Resistance Level | $62.67 | $14.00 |
| Average True Range (ATR) | 1.28 | 0.70 |
| MACD | -0.20 | -0.13 |
| Stochastic Oscillator | 37.27 | 9.12 |
Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.